Plasma and serum biomarkers for Hodgkin lymphoma

霍奇金淋巴瘤的血浆和血清生物标志物

• 批准号: 8913087
• 负责人: RICHARD Frederick AMBINDER
• 金额: $ 17.84万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-15 至 2017-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8913087
• 关键词: Accounting; Biological Assay; Biological Markers; Blood; Blood Tests; Blood specimen; CCL17 gene; Cells; Clinical; Clinical Trials; Complex; DNA; DNA Markers; Data; Data Set; Development; Early treatment; Evaluation; Fertility; Freedom; Gene Expression; Health; Hodgkin Disease; Human Herpesvirus 4; Immunohistochemistry; In Situ Hybridization; Infectious Mononucleosis; Inflammatory Infiltrate; Lead; Measurement; Measures; Methylation; Nasopharynx Carcinoma; Noise; Occupations; Outcome; Pathologic; Patients; Pilot Projects; Plasma; Prognostic Factor; Proteins; Quality of life; Randomized; Regimen; Salvage Therapy; Second Primary Cancers; Second Primary Neoplasms; Serum; Signal Transduction; Staging; Surveys; Time; Toxic effect; Treatment Protocols; Treatment outcome; Tumor Markers; Validation; Viral; Virion; alternative treatment; base; cancer cell; clinical decision-making; cost; high risk; improved; indexing; interest; molecular marker; mortality; neoplastic cell; outcome forecast; prognostic; prognostic tool; response; tool development; treatment response; treatment strategy; tumor DNA; viral DNA

DESCRIPTION (provided by applicant): Advanced stage Hodgkin lymphoma (HL) is usually cured. However, there remains an important fraction of patients who fail therapy, and others who develop late, sometimes fatal, complications of therapy. An intensive treatment regimen results in a higher up front cure rate but at the cost of more second malignancies, fertility loss, and other long-term toxicities. There is a less intensive regimen that yields fewer upfront cures, fewer second malignancies, less fertility loss and fewer long-term toxicities. After taking the result of salvage therapies into account, the approaches generate very similar long term overall survival. If it were possible to target only high risk patients to the more intensive therapy, the upfront cure rate associated with the more intensive therapy might be maintained, while the second malignancies and other toxicities might be minimized in those patients not treated intensively. Our focus in this pilot application is to evaluate previously identified blood-based molecular markers as predictors of response and outcome in patients with advanced HL. We seek to extend the evaluation of molecular markers to include early time points that might be most helpful in guiding decisions about therapy. The markers to be studied will include EBV DNA, sCD30, TARC, sCD163 and sBLyS. We also will evaluate an EBV DNA assay refinement that we anticipate will diminish the noise associated with standard measurements in cell-free blood. The proposed studies will be carried out in the context of a large randomized cooperative group study (E2496) comparing ABVD and Stanford V. The study is complete, clinical and pathologic annotation, and long term outcomes are available.

描述（由申请人提供）：晚期霍奇金淋巴瘤（HL）通常可以治愈。然而，仍然有很大一部分患者治疗失败，还有一些患者出现晚期，有时是致命的治疗并发症。强化治疗方案的结果是更高的前期治愈率，但代价是更多的二次恶性肿瘤，生育能力丧失，